Mobile App

Google Play Apple Store
Recent and Emerging Research in Pulmonary Arterial Hypertension - Updated 12/8/2022
AMA/ANCC/ACPE Activity - Lecture Library Slide Set
Simply Speaking PAH includes a curriculum that highlights the very latest clinical data in pulmonary arterial hypertension (PAH). Slides are developed and updated throughout the year by leading PAH expert physicians. All content is reviewed and approved by the Simply Speaking PAH Planning Committee.

Over the past two decades, research has vastly improved the understanding of the pathophysiology, diagnosis and treatment of PAH. While no therapies have been approved to target new mechanisms of action in more than 5 years, several phase 2 and phase 3 clinical trials of novel targets have begun. Improvements in the care of PAH patients depends on improving clinician awareness of the latest research into new diagnostic techniques, medications, and monitoring. This slide kit brings cutting-edge research to busy clinicians enabling them to readily keep abreast of the published research.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.
Review the activity and claim AMA, ANCC or ACPE credit/contact hour after completion of a brief pretest and posttest/evaluation.
Robert Schilz, DO, PhD
Robert Schilz, DO, PhD
Director, Pulmonary Vascular Disease and Lung Transplantation
University Hospitals Cleveland Medical Center
Associate Professor
Case Western Reserve University School of Medicine







20

Supported by independent educational grants from

United Therapeutics Corporation, Bayer U.S.

and Actelion Pharmaceuticals U.S., Inc.,

A Janssen Pharmaceutical Company of Johnson & Johnson


Launch Date: June 13, 2022

Release Date: February 1, 2022

Expiration Date: April 30, 2023

April 30, 2023
Mini Module
7372
SSLectureLibrary22_WebBannerPAH(1150).gif
Pulmonology